Breaking News

Danaher to buy Pall Corporation for $14bn

By Dan Stanton contact

- Last updated on GMT

Danaher to buy Pall Corporation for $14bn
Pall has agreed to be acquired by Danaher Corporation for $13.8bn (€12bn).

Yesterday this publication reported rumours that Pall Corporation was being eyed up by Thermo Fisher and Danaher.

The filtration, separation and purification tech firm is set to be incorporated into Danaher after the company agreed this morning to be acquired for $127.20 per share in cash.

Pall CEO Larry Kingsley said the transaction created an “opportunity for long-term growth”​ and that his company is a complementary fit for Danaher.

“Danaher's proven management system and strong financial position coupled with Pall's expertise, brand and channel strength in the field of filtration and separation science [will enable] the creation of tremendous value for the global customers of the combined company.”

Yesterday, this publication reported​ Danaher had entered a bidding war with Thermo Fisher, with several analysts saying the firm was highly attractive to both, though Pall’s biopharma assets were deemed more of an obvious fit for Thermo Fisher.

The transaction is expected to close around the end of the year.

On the back of this deal, Danaher has said it intends to split into two independent, publicly traded companies: A science and technology growth company which will include the Pall business and will retain the Danaher name, and a diversified industrial growth company.

"The pending strategic acquisition of Pall Corporation announced today offers us the unique opportunity to drive greater shareholder value going forward as two stronger and better companies,"​ said Danaher CEO Thomas Joyce, adding "each company will be more focused with access to the capital necessary to pursue organic and inorganic growth opportunities."

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us

Products

View more

Webinars